Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.84 - $16.79 $29,008 - $62,123
3,700 Added 36.63%
13,800 $114,000
Q1 2024

May 15, 2024

BUY
$13.2 - $17.76 $93,720 - $126,096
7,100 Added 236.67%
10,100 $179,000
Q4 2023

Feb 14, 2024

BUY
$6.52 - $20.32 $652 - $2,032
100 Added 3.45%
3,000 $56,000
Q3 2023

Nov 14, 2023

BUY
$6.02 - $7.76 $17,458 - $22,504
2,900 New
2,900 $20,000
Q1 2023

May 15, 2023

BUY
$7.36 - $12.72 $8,096 - $13,992
1,100 Added 78.57%
2,500 $20,000
Q4 2022

Feb 14, 2023

BUY
$7.02 - $9.76 $9,828 - $13,664
1,400 New
1,400 $12,000

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $1.53B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.